Insurance

Interview With Allen S. Lichter, MD, Chief Executive Officer, American Society of Clinical Oncology

Panelists agree that congress does not want these cuts in physician payment rates and Medicare.

The panel members discuss the question of how much would it cost to abolish the SGR.

Panel members discuss the fundamental problems with the SGR formula.

Dr. Butler answers why he is not confident that costs will ever be controlled.

To improve formulary design processes and support payers in providing more effective healthcare, policy makers should consider involving commercial payers in the development of comparative effectiveness research and creation of research and treatment guidelines.

As calls for improving the quality and cost efficiency of oncology increase, future empirical work is needed to examine the responsiveness of oncologists' treatment decision making to incentives among patients of all ages and insurance types.